Strategic partnership GenNext has recent high-profile partnerships with Thermo Fisher Scientific and Agilent Technologies, signaling strong credibility and a potential entry point for co-sell opportunities, expanded workflows, and integrated solutions for protein structure analysis.

Workflow expansion The AutoFox Protein Footprinting System integrates into existing LC/MS platforms and offers streamlined workflows for epitope mapping, aggregation analysis, and biosimilarity assessments, creating opportunities to upsell additional modules, services, or bundled offerings to biopharma clients.

Biologics focus Attention to biotherapeutics, monoclonal antibodies, and AI-generated models suggests targeting mid-market biologics developers and CROs seeking high-resolution structural data, with potential for repeat-contract services and long-term instrumentation licensing.

Proof of value Customer value is framed around time and cost savings with high-resolution, reproducible data, presenting a sales angle centered on reducing drug development timelines and improving safety/efficacy profiles for biopharmaceuticals.

Growth signals Recent funding and a growing partner network indicate scalability potential; use this to prospect for channel partnerships, VAR models, or expansion into adjacent markets such as small-molecule analytics and AI-driven modeling collaborations.